{"url_path":"/sec/autl/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000065-index.html","accession_number":"0001730463-26-000065","cik":"0001730463","ticker":"AUTL","issuer_name":"Autolus Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000065-index.html","primary_entity_key":"0001730463","primary_entity_name":"Autolus Therapeutics plc"},"word_count":357,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nThe following exhibits are either provided with this Quarterly Report on Form 10-Q or are incorporated herein by reference:\n\nExhibit numberDescription\n\n[3.1](https://www.sec.gov/Archives/edgar/data/1730463/000119312518196344/d531832dex31.htm)\n\n[Articles of Association of Autolus Therapeutics plc (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form F-1 (file no: 333-224720))](https://www.sec.gov/Archives/edgar/data/1730463/000119312518196344/d531832dex31.htm)\n\n[10.1*](ex-101agcmsaandsow1.htm)\n\n[Master Supply Agreement](ex-101agcmsaandsow1.htm)[and Statement of Work 1](ex-101agcmsaandsow1.htm)[, dated January](ex-101agcmsaandsow1.htm)[21](ex-101agcmsaandsow1.htm)[, 2026](ex-101agcmsaandsow1.htm)[and](ex-101agcmsaandsow1.htm)[March 17](ex-101agcmsaandsow1.htm)[, 2026](ex-101agcmsaandsow1.htm)[, respectively](ex-101agcmsaandsow1.htm)[,](ex-101agcmsaandsow1.htm)[between Autolus Limited and](ex-101agcmsaandsow1.htm)[AGC Biologics S.p.A.](ex-101agcmsaandsow1.htm)\n\n[31.1*](autolus-10xqx03312026ex311.htm)\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](autolus-10xqx03312026ex311.htm)\n\n[31.2*](autolus-10xqx03312026ex312.htm)\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](autolus-10xqx03312026ex312.htm)\n\n[32.1**](autolus-10xqx03312026ex321.htm)\n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](autolus-10xqx03312026ex321.htm)\n\n101.INS*Inline XBRL Instance Document\n\n101.SCH*\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n*\n\nFiled herewith\n\n**\n\nThis certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n41\n\n[Table of contents](#i6bc77efb1608460996703cf654719a76_7)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n Autolus Therapeutics plc\n\n \n\nDate: May 14, 2026By:\n/s/ Christian Itin, Ph.D.\n\n  NameChristian Itin, Ph.D.\n\n  Title:Chief Executive Officer\n\n(On Behalf of the Registrant and as Principal Executive Officer)\n\nDate:May 14, 2026By:/s/ Robert Dolski\n\nNameRobert Dolski\n\nTitle:Chief Financial Officer\n\n(Principal Financial Officer)\n\n42"}